Predictors of Delayed Therapy after Expectant Management for Localized Prostate Cancer in the Era of Prostate-Specific Antigen
- 1 November 2004
- journal article
- Published by S. Karger AG in Oncology
- Vol. 67 (3-4) , 194-202
- https://doi.org/10.1159/000081317
Abstract
To identify risk factors for delayed cancer-directed intervention in modern era prostate cancer patients who initially elect expectant management. An observational, cohort study of expectantly managed patients, diagnosed with clinical T(1-4)NxM0 prostate cancer between 1993 and 2000 was carried out. Data including TNM stage, age, serum prostate-specific antigen (PSA), prostate gland volume by transrectal ultrasound, Gleason score, percent biopsies positive for cancer, imaging results, initial treatment selection, and outcome data were collected on all patients. 192 of 561 patients (34.3%) elected expectant management, and follow-up data were available for 187 (97.4%) patients. With a median follow-up of 3.6 years, 90 (48.1%) patients had a cancer-directed intervention. Gleason score (p = 0.0097) and percent of positive biopsy cores (p = 0.03) were independent predictors of time to intervention. As expected, PSA doubling time became the most significant predictor of intervention (p = 0.0057) when added to the model. These independent covariates are able to characterize low-, intermediate- and high-risk groups for cancer-directed intervention. Cancer-directed intervention is common in patients who choose expectant management in the PSA era. Gleason score and percent of positive biopsy cores predict cancer-directed interventions, thus, these patients may be least suitable for expectant management.Keywords
This publication has 16 references indexed in Scilit:
- A Randomized Trial Comparing Radical Prostatectomy with Watchful Waiting in Early Prostate CancerNew England Journal of Medicine, 2002
- Feasibility Study: Watchful Waiting For Localized Low To Intermediate Grade Prostate Carcinoma With Selective Delayed Intervention Based On Prostate Specific Antigen, Histological And/Or Clinical ProgressionJournal of Urology, 2002
- Prostate cancer trends in the era of prostate-specific antigenUrologic Clinics of North America, 2002
- CONSERVATIVE MANAGEMENT OF PROSTATE CANCER IN THE PROSTATE SPECIFIC ANTIGEN ERAJournal of Urology, 2001
- EVALUATION OF CHANGES IN PROSTATE SPECIFIC ANTIGEN IN CLINICALLY LOCALIZED PROSTATE CANCER MANAGED WITHOUT INITIAL THERAPYJournal of Urology, 1998
- Deferred treatment of clinically localized low-grade prostate cancer: Actual 10-year and projected 15-year follow-up of the karolinska seriesUrology, 1997
- Fifteen-year survival in prostate cancer. A prospective, population-based study in SwedenJAMA, 1997
- Long-term survival among men with conservatively treated localized prostate cancerPublished by American Medical Association (AMA) ,1995
- Results of Conservative Management of Clinically Localized Prostate CancerNew England Journal of Medicine, 1994
- Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate diseaseJAMA, 1992